Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01548222Completed

CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target

Role: lead

NCT01377155Not ApplicableCompleted

A Comparison of Two Initial Dosing Formulas

Role: lead

NCT00874809Not ApplicableCompleted

Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study

Role: lead

NCT00457093Not ApplicableCompleted

A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes

Role: lead

NCT01045954Not ApplicableUnknown

A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections

Role: lead

NCT00460304Not ApplicableCompleted

The Effect of Pramlintide on Meal Time Insulin Bolus

Role: lead

All 6 trials loaded